Kintara Therapeutics, Inc. (KTRA)
| Market Cap | 45.67M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -38.59M |
| Shares Out | 29.27M |
| EPS (ttm) | -1.87 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 510,297 |
| Open | 1.37 |
| Previous Close | 1.40 |
| Day's Range | 1.27 - 1.39 |
| 52-Week Range | 1.18 - 3.35 |
| Beta | 1.54 |
| Analysts | n/a |
| Price Target | 5.81 (+346.9%) |
| Est. Earnings Date | n/a |
About KTRA
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic b...
Financial Performance
Financial StatementsNews
Kintara Therapeutics Provides Positive Site Activation Update on GCAR Phase 2/3 Clinical Trial for Glioblastoma
SAN DIEGO, Aug. 17, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapie...
Kintara Therapeutics to Present at the Investor Summit Virtual Conference on August 17, 2021
SAN DIEGO, Aug. 12, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA), a biopharmaceutical company developing novel cancer therapies for patients who are failing or are resistant to current...
Kintara Therapeutics to Present at the BTIG Virtual Biotechnology Conference on August 9, 2021
SAN DIEGO, Aug. 4, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA), a biopharmaceutical company developing novel cancer therapies for patients who are failing or are resistant to current ...
Kintara Therapeutics Shows Encouraging Safety, Efficacy Data From Brain Cancer Study With VAL-083
Kintara Therapeutics Inc (NASDAQ: KTRA) has announced topline data from Phase 2 study of its lead compound VAL-083, conducted at the MD Anderson Cancer Center. The Phase 2 trial is a two-arm, biomarker-...
Kintara Reports Topline Results From Phase 2 Clinical Trial of VAL-083 for Recurrent GBM
SAN DIEGO, July 1, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company developing novel cancer therapies for patients who are failing...
Kintara Therapeutics set to join the Russell Microcap Index
Kintara Therapeutics Inc (NASDAQ:KTRA) (OTCMKTS:DMPWW) (FRA:3DM), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, has announced its addition to the Russell Mi...
Kintara Therapeutics Set to Join Russell Microcap® Index
SAN DIEGO, June 7, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies...
Dow pulls to above the flatline after morning struggles as traders digest jobs data
12:30pm: Nasdaq finds little upward momentum The Dow clawed its way out of an early deficit to 15 points higher at midday at 34,615. The Nasdaq was down 117 points, 0.9%, at 13,641, and the S&P 500 shed...
Kintara Therapeutics enrolls last patient in Phase 2 VAL-083 trial for glioblastoma multiforme
Kintara Therapeutics Inc (NASDAQ:KTRA) (FRA:3DM) announced it has enrolled the final patient in the adjuvant arm of its ongoing Phase 2 clinical study of VAL-083 as a treatment for glioblastoma multifor...
Kintara Therapeutics Enrolls Final Patient in Phase 2 Clinical Trial of VAL-083 for Adjuvant Treatment of Brain Tumors
SAN DIEGO, June 3, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies...
Kintara Therapeutics to Present at the LD Micro Virtual Invitational Conference on June 9, 2021
SAN DIEGO, June 2, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced today that Chief ...
Kintara Stock Soars After Site Activation Update On Glioblastoma Trial
Kintara Therapeutics Inc (NASDAQ: KTRA) has announced that the VAL-083 treatment arm in the Global Coalition for Adaptive Research registrational Phase 2/3 trial for glioblastoma multiforme (GBM) has be...
Kintara Therapeutics says VAL-083 treatment arm in the Phase 2/3 clinical trial for glioblastoma multiforme has now b...
Kintara Therapeutics, Inc. (NASDAQ:KTRA) has announced that the VAL-083 treatment arm in the Global Coalition for Adaptive Research (GCAR) registrational Phase 2/3 clinical trial for glioblastoma multif...
Kintara Therapeutics, Inc. says VAL-083 treatment arm in the Phase 2/3 clinical trial for glioblastoma multiforme has...
Kintara Therapeutics, Inc. (NASDAQ:KTRA) has announced that the VAL-083 treatment arm in the Global Coalition for Adaptive Research (GCAR) registrational Phase 2/3 clinical trial for glioblastoma multif...
Kintara Therapeutics Provides Positive Site Activation Update on GCAR Phase 2/3 Clinical Trial for Glioblastoma
SAN DIEGO, May 26, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies...
Kintara Therapeutics draws Buy recommendation from Aegis Capital which maintains a $7 price target
Analysts at Aegis Capital Corp rated Kintara Therapeutics Inc (NASDAQ:KTRA) a 'Buy,' while maintaining a $7 share target price on the company which develops new solid tumor cancer therapies. The San Die...
Kintara Therapeutics ends fiscal 3Q with cash and cash equivalents of about $15.7M
Kintara Therapeutics Inc (NASDAQ:KTRA), which is focused on the development of new solid tumor cancer therapies, said it closed its fiscal third quarter with cash and cash equivalents of about $15.7 mil...
Kintara Therapeutics Announces Fiscal Third Quarter 2021 Financial Results and Provides Corporate Update
SAN DIEGO, May 14, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies...
Kintara Therapeutics appoints corporate finance veteran Tamara Seymour as its board director
Kintara Therapeutics Inc (NASDAQ:KTRA) has announced the appointment of corporate finance veteran Tamara Seymour to its board of directors. Seymour replaces John Liatos, who will continue in his role as...
Kintara Therapeutics Appoints Tamara A. Seymour to Board of Directors
SAN DIEGO, May 4, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,...
Kintara Therapeutics says interim Phase 2 study data on VAL-083 shows its potential as game-changing treatment option...
Kintara Therapeutics Inc (NASDAQ:KTRA) has announced interim data from two Phase 2 clinical trials of its lead compound, VAL-083 for glioblastoma multiforme (GBM), which continue to demonstrate its pote...
Wall Street starts in the red
10.15am: Proactive North America headlines: Genprex Inc (NASDAQ:GNPX) presents positive preclinical data for lung cancer drug REQORSA at American Association for Cancer Research meeting Kintara Therape...
Kintara Presents Updates on Two Phase 2 Clinical Trials at the 2021 American Association for Cancer Research Annual M...
SAN DIEGO, April 12, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company developing novel cancer therapies for patients who are faili...
Kintara Taking The Lead In Developing New And Innovative Rare Cancer Therapies
Kintara Therapeutics, Inc. Chief Executive Officer Saiid Zarrabian participated in the Benzinga Biotech Small Cap Conference held March 24-25, 2021. Kintara Therapeutics, Inc. (NASDAQ: KTRA) a biopharm...